Eosinophilic Esophagitis

AstraZeneca and Amgen reported that the 368-patient Phase III CROSSING trial of tezepelumab in eosinophilic esophagitis met both co-primary endpoints at Week 24: histologic remission and improvement in dysphagia. Both tested doses also met…